{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T14:11:09Z","timestamp":1654179069837},"reference-count":32,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2021.2021.0325","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T06:11:13Z","timestamp":1637907073000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma"],"prefix":"10.4274","author":[{"given":"Ahmet","family":"Seyhanl\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boran","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehra","family":"Ak\u015fit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Y\u00fcce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"\u00d6zkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O\u011fuz","family":"Altung\u00f6z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130nci","family":"Alacac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcner Hayri","family":"\u00d6zsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Kyle RA, Rajkumar SV. ASH 50th anniversary review. Blood 2008;111:2962-2972.","DOI":"10.1182\/blood-2007-10-078022"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"BG","year":"1975","unstructured":"2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","unstructured":"3. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project","volume":"27","author":"Avet-Loiseau H","year":"2013","unstructured":"4. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013;27:711-717.","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","article-title":"Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies","volume":"122","author":"Cavo","year":"2013","unstructured":"5. Cavo M, Salwender H, Rosi\u00f1ol L, Moreau P, Petrucci MT, Blau IW, Blad\u00e9 J, Attal M, Patriarca F, Weisel K, San Miguel JF, Avet-Loiseau H, Testoni N, Pfreundschuh M, Lahuerta JJ, Facon T, Pantani L, Scheid C, Gutierrez N, Marit G, Palumbo A, Martin ML, Caillot D, Goldschmidt H. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood 2013;122:767.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","unstructured":"6. Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience. J Clin Oncol 2013;31:2806-2809.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bjhh.2016.01.005","article-title":"Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells","volume":"38","author":"Kishimoto","year":"2016","unstructured":"7. Kishimoto RK, Freitas SLVVd, Ratis CA, Borri D, Sitnik R, Velloso EDRP. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter 2016;38:113-120.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"NC","year":"2011","unstructured":"8. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-4700.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0753-3322(02)00194-4","article-title":"Myeloma aetiology and epidemiology","volume":"56","author":"Morgan","year":"2002","unstructured":"9. Morgan G, Davies F, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002;56:223-234.","journal-title":"Biomed Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-0609.1995.tb00204.x","article-title":"Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients","volume":"54","author":"Sailer","year":"1995","unstructured":"10. Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol 1995;54:137-146.","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","unstructured":"11. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007;139:351-362.","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","unstructured":"12. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1309\/AJCPT5Y2JRIUUCUB","article-title":"Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma","volume":"137","author":"Babarovi\u0107","year":"2012","unstructured":"13. Babarovi\u0107 E, Valkovi\u0107 T, \u0160tifter S, Budisavljevi\u0107 I, Seili-Bekafigo I, Duleti\u0107-Na\u010dinovi\u0107 A, Lu\u010din K, Jonji\u0107 N. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma. Am J Clin Pathol 2012;137:870-878.","journal-title":"Am J Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1002\/cam4.3265","article-title":"The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and\/or proteasome inhibitors","volume":"9","author":"Paul","year":"2020","unstructured":"14. Paul B, Zhao Y, Loitsch G, Feinberg D, Mathews P, Barak I, Dupuis M, Li Z, Rein L, Wang E, Kang Y. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and\/or proteasome inhibitors. Cancer Med 2020;9:5869-5880.","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","unstructured":"15. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-1558.","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","unstructured":"16. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-2238.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3324\/haematol.2012.081083","article-title":"Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma","volume":"98","author":"Van Wier","year":"2013","unstructured":"17. Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica 2013;98:1586-1592.","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","unstructured":"18. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-2221.","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"KD","year":"2012","unstructured":"19. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-355.","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/leu.2014.102","article-title":"p53 haploinsufficiency and functional abnormalities in multiple myeloma","volume":"28","author":"Teoh","year":"2014","unstructured":"20. Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, Fonseca R, Chng WJ. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014;28:2066-2074.","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","article-title":"Clinical significance of TP53 mutation in myeloma","volume":"21","author":"Chng","year":"2007","unstructured":"21. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R. Clinical significance of TP53 mutation in myeloma. Leukemia 2007;21:582-584.","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Lod\u00e9","year":"2010","unstructured":"22. Lod\u00e9 L, Eveillard M, Trichet V, Soussi T, Wuill\u00e8me S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traull\u00e9 C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010;95:1973-1976.","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/gcc.20899","article-title":"The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide\u2010based therapy","volume":"50","author":"KD","year":"2011","unstructured":"23. Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide\u2010based therapy. Genes Chromosomes Cancer 2011;50:765-774.","journal-title":"Genes Chromosomes Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","unstructured":"24. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","unstructured":"25. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, Cabanas ED, Parker T, Nightingale M, Wechalekar A, Orchard KH, Harrison CJ, Cross NC, Morgan GJ, Ross FM. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-1617.","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.leu.2404413","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Guti\u00e9rrez NC","year":"2007","unstructured":"26. Guti\u00e9rrez NC, Castellanos MV, Mart\u00edn ML, Mateos MV, Hern\u00e1ndez JM, Fern\u00e1ndez M, Carrera D, Rosi\u00f1ol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hern\u00e1ndez-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM\/PETHEMA Spanish Group. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-150.","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"PL","year":"2001","unstructured":"27. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-5622.","journal-title":"Oncogene"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","unstructured":"28. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blad\u00e9 J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955-2962.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Avet-Loiseau H, Moreau P, Mathiot C, Charbonnel C, Facon T, Attal M, Hulin C, Marit G, Minvielle S, Harousseau J; Intergroupe Francophone du My\u00e9lome. Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma. J Clin Oncol 2010;28(15 Suppl):8113.","DOI":"10.1200\/jco.2010.28.15_suppl.8113"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"JD Jr","year":"2007","unstructured":"30. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284.","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","unstructured":"31. Decaux O, Lod\u00e9 L, Magrangeas F, Charbonnel C, Gouraud W, J\u00e9z\u00e9quel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du My\u00e9lome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome. J Clin Oncol 2008;26:4798-4805.","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","unstructured":"32. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. A gene expression signature for high-risk multiple myeloma. Leukemia 2012;26:2406-2413.","journal-title":"Leukemia"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:30:17Z","timestamp":1654176617000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-67026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":32,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2021.2021.0325","relation":{},"ISSN":["1300-7777"],"issn-type":[{"value":"1300-7777","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,26]]}}}